Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Trimel Pharma Completes Patient Enrolment Of CompleoTRT Phase III Trial

7/23/2012 7:35 AM ET

Trimel Pharmaceuticals Corp. (TRL.TO: Quote) announced the completion of enrolment and randomization of 304 patients in the Phase III clinical trial evaluating CompleoTRT in patients with male hypogonadism or more commonly referred to as "Low T". The unique delivery of CompleoTRT is designed to provide hypogonadal men with the therapeutic effect of restoring testosterone levels while doing so with a micro volume amount of drug in the form of a bioadhesive intranasal gel.

The pivotal Phase III clinical trial, which was initiated in October 2011, is a randomized study in which patients are administered CompleoTRT and evaluated for efficacy after 90 days of treatment using the pharmacokinetic endpoint established for Low T therapies.

The Phase III study in its entirety represents the final stage of product development prior to the submission of a New Drug Application to the Food and Drug Administration for marketing approval in the United States.

Efficacy results from the Phase III clinical trial are expected to be available in the fourth quarter of 2012.

Click here to receive FREE breaking news email alerts for Trimel Pharmaceuticals Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
There was a mixed performance on Wall Street on Friday. Shares suffered an early decline, as investors continued to express worries about the Federal Reserve. A recovery through the rest of the day allowed the Dow to edge into positive territory by the close. The Nasdaq and S&P 500 posted fractional losses. Stocks have shown a notable move to the downside in early trading on Friday amid lingering concerns about the outlook for the Federal Reserve's asset purchase program. The major averages have slid firmly into negative territory, adding to the modest losses posted in the previous session. The major averages are currently posting notable losses, near their lows for the young session. After reporting a sharp drop in new orders for manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than anticipated in the month of April. The report said durable goods orders surged up by 3.3 percent in April after tumbling by a revised 5.9 percent in March.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.